• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PharmAthene, Theraclone Sciences merge

PharmAthene, Theraclone Sciences merge

August 5, 2013
CenterWatch Staff

PharmAthene and Theraclone Sciences, a privately-held monoclonal antibody (mAb) discovery and development company, have signed a definitive merger agreement.

The all-stock transaction has been unanimously approved by both boards of directors and is subject to shareholder and regulatory approval. PharmAthene will issue shares of PharmAthene common stock to Theraclone stockholders; Theraclone stockholders will own 50% of the combined company.

Clifford J. Stocks, chief executive officer of Theraclone, will be president and CEO of the merged company.  Eric I. Richman will become director of the combined company's board.

The company will be a fully-integrated and diversified biologics company with four clinical-stage product candidates targeting high-value commercial and government markets. It will combine vaccine and human monoclonal antibody expertise with a focus on infectious diseases and oncology, and will have a discovery pipeline with four preclinical programs and multiple discovery candidates, along with three partnered products.

Clinical stage product candidates following the merger will be TCN-202 CMV antibody being developed for the prevention and treatment of human cytomegalovirus (CMV) infections, TCN-032 influenza antibody being developed for the treatment of pandemic and severe seasonal influenza, SparVax anthrax vaccine and Valortim anthrax anti-toxin.

The merged company will feature a preclinical pipeline driven by the proprietary I-STAR memory B-cell interrogation platform, which facilitates the discovery of human antibodies against novel targets. Theraclone has an established collaboration with Pfizer for specific infectious disease and oncology indications for which it has received upfront payments and research funding and may receive development and commercialization milestones and royalties on product sales in the future based on successful advancement.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing